磷脂酶A2受体1促进阻塞性肺疾病中的肺细胞衰老与肺气肿
该研究探讨PLA2R1在COPD肺细胞衰老及肺气肿发病中的作用。COPD患者肺组织及培养细胞中PLA2R1过表达,敲低可延长细胞倍增能力并抑制SASP,ruxolitinib可逆转PLA2R1介导的衰老。PLA2R1过表达小鼠出现肺细胞衰老、肺气肿、肺纤维化及肺动脉高压,ruxolitinib可逆转肺气肿和纤维化;LV-PLA2R1小鼠4周内发生肺气肿,ruxolitinib显著减轻。提示靶向JAK1/2可能为COPD治疗策略。
要点
- COPD肺组织多种衰老细胞中PLA2R1过表达,敲低可抑制SASP。
- JAK1/2抑制剂ruxolitinib可逆转PLA2R1介导的COPD细胞衰老。
- PLA2R1过表达小鼠出现肺气肿、纤维化及肺动脉高压,ruxolitinib可逆转。
核心结论
- PLA2R1激活在驱动COPD肺细胞衰老及肺部改变中起主要作用。
- 靶向JAK1/2可能代表COPD有前景的治疗途径。
研究设计与样本
- 评估COPD患者与对照者肺组织及培养肺细胞的细胞衰老,并进行PLA2R1敲低、基因转导及ruxolitinib处理。
- 构建过表达PLA2R1的转基因小鼠,并向野生型小鼠气管内注射携带Pla2r1基因的慢病毒载体。
主要发现
- COPD肺中多种具衰老特征的细胞类型过表达PLA2R1。
- PLA2R1敲低延长这些细胞的群体倍增能力并抑制其促炎SASP。
- ruxolitinib大幅逆转COPD中PLA2R1介导的细胞衰老。
- 5月龄PLA2R1-TG小鼠出现肺细胞衰老、肺气肿、肺纤维化及肺动脉高压,ruxolitinib可逆转肺气肿和纤维化。
- LV-PLA2R1小鼠4周内发生肺气肿, concomitant ruxolitinib treatment显著减轻。
临床怎么用
- PLA2R1可作为COPD肺细胞衰老及肺气肿相关改变的潜在干预靶点。
- JAK1/2抑制剂ruxolitinib在实验模型中逆转衰老相关肺气肿和纤维化,支持进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cell senescence is a key process in age-associated dysfunction and diseases, notably chronic obstructive pulmonary disease (COPD). We previously identified phospholipase A2 receptor 1 (PLA2R1) as a positive regulator of cell senescence acting via Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling. Its role in pathology, however, remains unknown. Here, we assessed PLA2R1-induced senescence in COPD and lung emphysema pathogenesis. METHODS: We assessed cell senescence in lungs and cultured lung cells from patients with COPD and controls subjected to PLA2R1 knockdown, PLA2R1 gene transduction and treatment with the JAK1/2 inhibitor ruxolitinib. To assess whether PLA2R1 upregulation caused lung lesions, we developed transgenic mice overexpressing PLA2R1 (PLA2R1-TG) and intratracheally injected wild-type mice with a lentiviral vector carrying the Pla2r1 gene (LV-PLA2R1 mice). RESULTS: We found that PLA2R1 was overexpressed in various cell types exhibiting senescence characteristics in COPD lungs. PLA2R1 knockdown extended the population doubling capacity of these cells and inhibited their pro-inflammatory senescence-associated secretory phenotype (SASP). PLA2R1-mediated cell senescence in COPD was largely reversed by treatment with the potent JAK1/2 inhibitor ruxolitinib. Five-month-old PLA2R1-TG mice exhibited lung cell senescence, and developed lung emphysema and lung fibrosis together with pulmonary hypertension. Treatment with ruxolitinib induced reversal of lung emphysema and fibrosis. LV-PLA2R1-treated mice developed lung emphysema within 4 weeks and this was markedly attenuated by concomitant ruxolitinib treatment. CONCLUSIONS: Our data support a major role for PLA2R1 activation in driving lung cell senescence and lung alterations in COPD. Targeting JAK1/2 may represent a promising therapeutic approach for COPD.
引用
- Beaulieu D, Attwe A, Breau M, et al. Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease. Eur Respir J. 2021. PMID: 33509955. doi:10.1183/13993003.00752-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。